ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1579

Association of Myocardial Abnormalities with N-Terminal Pro-Brain Natriuretic Peptide and Disease Activity in Rheumatoid Arthritis without Cardiac Symptoms, Assessed By Cardiac Magnetic Resonance Imaging

Hitomi Kobayashi1, Yasuyuki Kobayashi2, Isamu Yokoe3, Natsumi Ikumi4,5, Hirotake Inomata6, Atsuma Nishiwaki6, Noboru Kitamura1, Kaita Sugiyama6, Hidetake Shiraiwa6, Masataka Nozaki6, Yosuke Nagasawa6, Yoshihiro Matsukawa5 and Masami Takei1, 1Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, 2Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, 3Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, 4Nihon University School of Medicine, Shinjuku, Japan, 5Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, 6Nihon University School of Medicine, Tokyo, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers, Cardiovascular disease, Disease Activity, magnetic resonance imaging (MRI) and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is a multi-organ inflammatory disorder associated with high cardiovascular morbidity and mortality. Cardiac involvements are typically clinically silent, only manifesting as heart failure after an extended subclinical phase. Myocardial abnormalities may arise from a number of distinct processes, including myocardial inflammation and/or myocardial fibrosis, any of which may be active in RA. We aimed to assess cardiac involvements using a cardiac magnetic resonance imaging (CMR) approach and to determine its association with disease characteristics and N-terminal pro-brain natriuretic peptide (NT-proBNP ) level in RA patients without cardiac symptoms.

Methods: Consecutive RA patients without cardiac symptoms were enrolled. RA patients with no history and/or clinical findings of systemic and pulmonary hypertension, coronary artery disease, valvular heart disease, atrial fibrillation, diabetes mellitus, and dyslipidemia underwent CMR. RA patients received conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or biologic DMARDs (bDMARDs). Late gadolinium enhancement (LGE) was obtained for the assessment of myocardial fibrosis. Using Black-Blood T2-weighted image (T2-WI), myocardial inflammation could be assessed. We evaluated the prevalence of CMR abnormalities, and investigated possible associations of CMR abnormalities with RA disease characteristics, and NT-proBNP level.

Results: Sixty patients (mean age, 55.2 ± 1.3 years; 85% female) were enrolled. Thirty RA patients received csDMARDs [25, methotrexate (MTX) (8.7±2.1mg); 5, other drugs)] and 30 RA patients received bDMARDs [15, infliximab 3 mg/kg; 15, tocilizumab 8 mg/kg plus methotrexate (8.6±1.4 mg) ]. Twenty RA patients (33%) demonstrated myocardial abnormalities. High intensity on T2-WI was seen in seven RA patients (11%). LGE was found in 19 RA patients (32%), six of whom also demonstrated high intensity on T2-WI. Simplified Disease Activity Index (SDAI) scores were significantly higher in LGE-positive compared to LGE-negative (p=0.011). LGE was significantly associated with high NT-proBNP and SDAI (p=0.005, p=0.018, respectively). The use of bDMARDs was significantly associated with LGE-negative findings (p=0.0017). Other RA characteristics such as disease duration, autoantibody status, and cardiovascular risk factors were not significantly associated with myocardial abnormalities. After adjusting for confounding by age, RA duration, rheumatoid factor and bDMARDs, the association of LGE with SDAI remained significant (p=0.023), in which the SDAI scores were, on average, 10.9 units higher in LGE-positive than in LGE-negative. Receiver operating characteristic analysis showed NT-proBNP reliably detected myocardial abnormalities (area under the curve 0.856; 95% confidence interval, 0.833–0.904).

Conclusion: Subclinical myocardial abnormalities are common in RA patients without cardiac symptoms, associated with SDAI and NT-proBNP level. NT-proBNP level reliably detected the presence of cardiac involvements appeares to be useful markers to risk stratify RA patients.


Disclosure: H. Kobayashi, None; Y. Kobayashi, None; I. Yokoe, None; N. Ikumi, None; H. Inomata, None; A. Nishiwaki, None; N. Kitamura, None; K. Sugiyama, None; H. Shiraiwa, None; M. Nozaki, None; Y. Nagasawa, None; Y. Matsukawa, None; M. Takei, None.

To cite this abstract in AMA style:

Kobayashi H, Kobayashi Y, Yokoe I, Ikumi N, Inomata H, Nishiwaki A, Kitamura N, Sugiyama K, Shiraiwa H, Nozaki M, Nagasawa Y, Matsukawa Y, Takei M. Association of Myocardial Abnormalities with N-Terminal Pro-Brain Natriuretic Peptide and Disease Activity in Rheumatoid Arthritis without Cardiac Symptoms, Assessed By Cardiac Magnetic Resonance Imaging [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/association-of-myocardial-abnormalities-with-n-terminal-pro-brain-natriuretic-peptide-and-disease-activity-in-rheumatoid-arthritis-without-cardiac-symptoms-assessed-by-cardiac-magnetic-resonance-imag/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-myocardial-abnormalities-with-n-terminal-pro-brain-natriuretic-peptide-and-disease-activity-in-rheumatoid-arthritis-without-cardiac-symptoms-assessed-by-cardiac-magnetic-resonance-imag/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology